Following surgery and chemotherapy for stage 1 triple-negative breast cancer, Karen took charge of her cancer narrative by researching other treatment options and talking to experts during a brief period of remission. When her cancer returned in 2017—this time metastatic—she was facing a life expectancy of 18 to 24 months, but she was prepared to try something new. She enrolled in a phase 1 trial at NYU Langone’s Perlmutter Cancer Center combining two immunotherapies: bempegaldesleukin (BEMPEG; NKTR-214) and nivolumab (Opdivo®). Her first CT scan, after eight weeks of immunotherapy, revealed a 72 percent reduction in tumors. In June 2020, Karen’s oncologist declared her “an official complete responder.” Her cancer immunotherapy experience has impassioned her to become a patient advocate and CRI ImmunoAdvocate.